Literature DB >> 9285509

Blood glucose control and microvascular and macrovascular complications in diabetes.

K F Hanssen1.   

Abstract

High blood glucose levels for several years is the major factor in the development and progression of microvascular complications in IDDM. Reducing mean blood glucose reduces the risk of progression of diabetic microvascular complications substantially. A curve-linear relationship exists between HbA1c levels and progression of diabetic retinopathy. Recent evidence also points to a close relationship between high blood glucose levels and progression of microvascular complications in NIDDM. The relationship between mean blood glucose and cardiovascular disease in diabetes has been unclear. Recent population-based studies give evidence for a linear association of glycemic control with the risk for cardiovascular disease in patients with NIDDM. However, randomized studies comparing different degrees of glycemic control in NIDDM and their impact on cardiovascular morbidity and mortality are urgently needed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285509     DOI: 10.2337/diab.46.2.s101

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  17 in total

1.  Changes in glycoprotein components in streptozotocin--nicotinamide induced type 2 diabetes: influence of tetrahydrocurcumin from Curcuma longa.

Authors:  Leelavinothan Pari; Pidaran Murugan
Journal:  Plant Foods Hum Nutr       Date:  2007-01-17       Impact factor: 3.921

2.  Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.

Authors:  T Shibata; S Takeuchi; S Yokota; K Kakimoto; F Yonemori; K Wakitani
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

Review 3.  Advanced glycation end products and diabetic retinopathy.

Authors:  Yashodhara Sharma; Sandeep Saxena; Arvind Mishra; Anita Saxena; Shankar Madhav Natu
Journal:  J Ocul Biol Dis Infor       Date:  2013-04-19

4.  Glycaemia Status, Lipid Profile and Renal Parameters in Progressive Diabetic Neuropathy.

Authors:  Debahuti Mohapatra; Komaladevi Sampath Damodar
Journal:  J Clin Diagn Res       Date:  2016-09-01

5.  Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction.

Authors:  Yang Hu; Ying Chen; Lexi Ding; Xuemin He; Yusuke Takahashi; Yang Gao; Wei Shen; Rui Cheng; Qian Chen; Xiaoping Qi; Michael E Boulton; Jian-xing Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-03       Impact factor: 11.205

Review 6.  Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus.

Authors:  A Evans; A J Krentz
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

7.  Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature.

Authors:  L Rodríguez-Mañas; J Angulo; S Vallejo; C Peiró; A Sánchez-Ferrer; E Cercas; P López-Dóriga; C F Sánchez-Ferrer
Journal:  Diabetologia       Date:  2003-03-12       Impact factor: 10.122

8.  The influence of type-1 diabetes mellitus on dentition and oral health in children and adolescents.

Authors:  Recep Orbak; Sera Simsek; Zerrin Orbak; Fahri Kavrut; Meltem Colak
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

9.  Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets.

Authors:  Wai Ho Tang; Jeremiah Stitham; Yu Jin; Renjing Liu; Seung Hee Lee; Jing Du; Gourg Atteya; Scott Gleim; Geralyn Spollett; Kathleen Martin; John Hwa
Journal:  Circulation       Date:  2014-01-28       Impact factor: 29.690

10.  Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products.

Authors:  J V Valencia; M Mone; C Koehne; J Rediske; T E Hughes
Journal:  Diabetologia       Date:  2004-05-01       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.